Rhein’s Protective Role Against Intestinal Injury in Severe Acute Pancreatitis

Research published on May 13, 2026, indicates that Rhein, a natural compound derived from aloe species and the rhubarb plant (Rheum palmatum), can mitigate intestinal injury associated with severe acute pancreatitis (SAP). The findings, led by Dr. Jun Yang at the Affiliated Hospital of Jiangnan University and published in the Chinese Medical Journal, suggest that the compound protects the gut barrier, potentially reducing the systemic inflammation that often leads to organ failure in SAP patients.

Severe acute pancreatitis is recognized as one of the most difficult clinical emergencies in gastroenterology. It is characterized by high rates of mortality and morbidity, driven largely by multiple organ dysfunction and overwhelming systemic inflammation.

While supportive care has advanced, therapeutic options for complications that occur outside the pancreas remain limited. A primary driver of disease severity is pancreatitis-associated intestinal injury (PAII), which acts as a second hit that amplifies the inflammatory response throughout the body.

This intestinal injury occurs when the gut barrier is disrupted, allowing luminal endotoxins and microbes to translocate into the systemic circulation. This breach further fuels the inflammatory cascade, exacerbating the patient’s condition.

The study identified a specific molecular axis that Rhein uses to exert its protective effects. The compound modulates macrophage activation via peroxisome proliferator-activated receptor gamma (PPARγ), which in turn regulates the NOD-like receptor protein 3 (NLRP3) inflammasome and macrophage polarization.

By targeting this pathway, Rhein helps maintain the integrity of the intestinal barrier. This barrier is a dynamic interface consisting of a monolayer of epithelial cells held together by tight junction proteins, including Occludin, Claudin-1, ZO-1, and ZO-2. These proteins are essential for maintaining selective permeability and preventing the ingress of bacteria into the bloodstream.

In experimental models using mice, the administration of Rhein resulted in several measurable improvements in pancreatic and intestinal health. Researchers observed a marked reduction in key biomarkers of pancreatic injury, specifically serum lipase and amylase levels.

Beyond biomarker levels, the treatment led to the attenuation of pancreatic necrosis, inflammatory infiltration, and edema. The most critical effect, however, was the profound protective impact on the intestinal compartment, which limited the damage typically seen in severe cases of pancreatitis.

The ability of Rhein to control macrophage activation suggests a targeted approach to reducing the hyper-inflammatory state associated with SAP. By preventing the breakdown of the intestinal wall, the compound effectively limits the source of secondary systemic inflammation.

The identification of the PPARγ-NLRP3 axis provides a clearer understanding of how anthraquinone derivatives like Rhein can be used to treat complex inflammatory conditions. This mechanism highlights the role of macrophage polarization in determining whether the body’s immune response contributes to tissue repair or further injury.

These findings offer a potential new direction for treating the systemic complications of severe acute pancreatitis, focusing on the gut-pancreas axis to prevent the progression toward multi-organ failure.